Sun Yat-sen University Cancer Center (SYSUCC): National Oncology Center Pioneering Precision Cancer Care

Established in 1964, Sun Yat-sen University Cancer Center (SYSUCC)—comprising the cancer hospital and cancer research institute—is one of the oldest, largest, and most prestigious Class A Tertiary specialized cancer hospitals in China. As a national medical center and designated National Clinical Research Center for Cancer, SYSUCC consistently ranks TOP 2 nationwide for oncology in the official Fudan University Chinese Hospital Rankings, standing at the forefront of global cancer research and clinical excellence.

World-Class Clinical Specialties & Breakthrough Strengths

1. 🔬 Nasopharyngeal Carcinoma (NPC) — Global Leader & Benchmark

SYSUCC operates the world's highest-volume and most academically distinguished center for the diagnosis and multidisciplinary management of nasopharyngeal carcinoma:

• Breakthrough Survival Rates: 5-year overall survival exceeds 85% to 90% for localized disease, and long-term disease-free survival remains unmatched globally.
• Precision Radiation Protocols: Pioneers of individualized intensity-modulated radiation therapy (IMRT) and adaptive radiation techniques that maximize tumor control while rigorously sparing salivary function, auditory structures, brainstem, and optic pathways.
• Pioneering Systemic Regimens: Led landmark global clinical trials establishing the standard-of-care induction chemotherapy and immunotherapy combinations for advanced and recurrent NPC.

2. 🫁 Thoracic Oncology (Lung & Esophageal Cancer)

One of the top thoracic oncology divisions in Asia, specializing in comprehensive surgical and medical treatment:

• Minimally Invasive Thoracic Surgery: Extensive expertise in robotic-assisted (Da Vinci) and uniportal video-assisted thoracoscopic surgery (VATS) for complex anatomical segmentectomies and sleeve resections.
• Genomic-Guided Precision Medicine: Routine deep-panel next-generation sequencing (NGS) targeting rare and common oncogenic drivers (EGFR, ALK, ROS1, KRAS G12C, MET, RET, HER2).
• Immuno-Oncology & Novel Combinations: Leading investigational centers for bispecific antibodies and antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

3. 🎀 Breast Oncology

Providing holistic, full-lifecycle breast cancer management:

• High rate of oncoplastic breast-conserving surgery and immediate autologous/implant-based breast reconstruction.
• Tailored neoadjuvant systemic therapy protocols for HER2-positive and triple-negative breast cancer (TNBC), achieving elevated pathologic complete response (pCR) rates.
• Comprehensive genetic counseling and BRCA1/2 screening programs.

4. 🩺 Hepatobiliary & Pancreatic Cancer

Equipped to handle difficult, advanced, and vascularly involved hepatobiliary malignancies:

• Hepatic Arterial Infusion Chemotherapy (HAIC): National pioneers in developing and standardizing FOLFOX-based HAIC, significantly converting unresectable hepatocellular carcinoma (HCC) into surgical resectability.
• Complex Resection & Reconstruction: High-precision anatomic hepatectomies and robotic pancreaticoduodenectomy (Whipple procedures) with vascular reconstruction.
• Combined Targeted & Immune Therapy: Systematic multimodal strategies integrating interventional radiology (TACE, ablation) with novel systemic agents.

5. 🔬 Gastrointestinal Oncology (Gastric & Colorectal Cancers)

Integrating advanced surgical precision with individualized perioperative regimens:

• Radical D2/D3 lymphadenectomy performed via 3D laparoscopic and robotic platforms.
• Hyperthermic Intraperitoneal Chemotherapy (HIPEC) protocols for selected patients with peritoneal carcinomatosis.
• Biomarker-guided immunotherapy pathways for microsatellite instability-high (MSI-H) and mismatch repair-deficient (dMMR) tumors.

6. 🩸 Hematologic Oncology & Lymphoma

Dedicated clinical teams specializing in rare and complex lymphoid neoplasms:

• Global leadership in peripheral T-cell and extranodal NK/T-cell lymphoma diagnosis and targeted therapeutics.
• Cellular immunotherapy capabilities including chimeric antigen receptor T-cell (CAR-T) clinical programs and next-generation targeted small molecules.

Distinguished Multidisciplinary Team (MDT) System

At SYSUCC, no complex case is evaluated in isolation. The hospital maintains daily, specialty-specific Multidisciplinary Tumor Boards (MDT) that assemble:

• Surgical oncologists and thoracic/abdominal surgeons
• Medical oncologists and cancer pharmacologists
• Radiation oncologists and medical physicists
• Subspecialty oncology pathologists
• Diagnostic and interventional radiologists

This integrated framework ensures that every patient receives a comprehensive, peer-reviewed treatment roadmap before irreversible therapeutic steps are taken.

China's Leading Center for Innovative Clinical Trials (GCP)

SYSUCC operates one of the most prolific National Drug Clinical Trial (GCP) centers in the Asia-Pacific region. International and cross-regional patients facing refractory, recurrent, or rare tumors have access to hundreds of active clinical trials covering:

• Next-generation Antibody-Drug Conjugates (ADCs) targeting TROP2, HER2, HER3, Claudin 18.2, and B7-H3;
• Bispecific and multi-specific T-cell engager antibodies;
• Novel tumor vaccines and personalized cellular therapies;
• Third- and fourth-generation tyrosine kinase inhibitors (TKIs).

Campus Locations & Facilities

• Yuexiu Main Campus: 651 Dongfeng East Road, Yuexiu District, Guangzhou, Guangdong, China (越秀区东风东路651号)
• Huangpu Science City Campus: 627 Kaitai Avenue, Huangpu District, Guangzhou, Guangdong, China (黄埔区开泰大道627号)
• Hospital Tier: Class A Tertiary Specialized Hospital (国家三级甲等肿瘤专科医院)

Recommended Medical Documents for International Evaluation

To facilitate thorough review by SYSUCC specialists, patients are encouraged to organize the following diagnostic records:

• Pathology Reports: Histopathology and complete immunohistochemistry (IHC) diagnostic panels;
• Molecular & Genomic Testing: Next-Generation Sequencing (NGS) reports, gene mutation/rearrangement assays, and PD-L1 expression scores;
• Digital Imaging: Original DICOM format files (CT, MRI, PET-CT, ultrasound) with corresponding radiology reports;
• Clinical Treatment History: Operative notes, radiation oncology discharge summaries (including radiation dose distribution and fields), systemic medication history with exact dosages and treatment cycles;
• Current Health Status: Recent complete blood count (CBC), liver and kidney biochemical profiles, and cardiopulmonary functional evaluations.

Disclaimer: Information on this page regarding Sun Yat-sen University Cancer Center (SYSUCC) is sourced from authoritative hospital announcements, official clinical registries, and peer-reviewed medical publications. Details concerning specific clinical departments, physician rosters, diagnostic protocols, and research programs are subject to change by the hospital. Always consult official hospital announcements or contact medical specialists directly for real-time verification.

Notice: China Medical Concierge - Shanghai (CMCS) is an independent health management and medical concierge service provider, not a hospital or clinic. We do not provide direct medical diagnoses or therapeutic treatments. All medical procedures and clinical evaluations are performed independently by licensed physicians at partner hospitals.